These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
132 related items for PubMed ID: 3177174
1. CI-930, a new cardiotonic and vasodilating agent: hemodynamic comparison to dobutamine and long-term clinical effects. Mancini D, Keren G, Sonnenblick EH, LeJemtel TH. Am Heart J; 1988 Oct; 116(4):1008-16. PubMed ID: 3177174 [Abstract] [Full Text] [Related]
2. Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure. Kieback AG, Iven H, Stolzenburg K, Baumann G. J Cardiovasc Pharmacol; 1998 Oct; 32(4):629-36. PubMed ID: 9781932 [Abstract] [Full Text] [Related]
3. Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure. Jafri SM, Burlew BS, Goldberg AD, Rogers A, Goldstein S. Am J Cardiol; 1986 Feb 01; 57(4):254-9. PubMed ID: 3511661 [Abstract] [Full Text] [Related]
4. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Maskin CS, Sinoway L, Chadwick B, Sonnenblick EH, Le Jemtel TH. Circulation; 1983 May 01; 67(5):1065-70. PubMed ID: 6831672 [Abstract] [Full Text] [Related]
11. Acute hemodynamic and hormonal effects of CI-930, a new phosphodiesterase inhibitor, in severe congestive heart failure. Murali S, Uretsky BF, Valdes AM, Kolesar JA, Reddy PS. Am J Cardiol; 1987 Jun 01; 59(15):1356-60. PubMed ID: 3591691 [Abstract] [Full Text] [Related]
12. [Enoximone/dobutamine comparison in chronic congestive cardiac insufficiency with low cardiac output]. Galinier M, Rochiccioli JP, Edouard P, Fourcade J, Massabuau P, Puel J, Fauvel JM, Bounhoure JP. Arch Mal Coeur Vaiss; 1990 Sep 01; 83 Spec No 3():27-32. PubMed ID: 2147831 [Abstract] [Full Text] [Related]
13. [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside]. Domínguez de Rozas JM, Guindo Soldevila J, Rodríguez Font E, Martínez Vílchez R. Rev Esp Cardiol; 1994 Oct 01; 47(10):682-6. PubMed ID: 7991922 [Abstract] [Full Text] [Related]
14. [Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery]. Alvarez J, Bouzada M, Fernández AL, Caruezo V, Taboada M, Rodríguez J, Ginesta V, Rubio J, García-Bengoechea JB, González-Juanatey JR. Rev Esp Cardiol; 2006 Apr 01; 59(4):338-45. PubMed ID: 16709386 [Abstract] [Full Text] [Related]